UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Journal of clinical oncology, 2008-04, Vol.26 (11), p.1810-1816

2008

Volltextzugriff (PDF)

Other Options in the Treatment of Advanced Breast Cancer

Seminars in oncology, 2011-06, Vol.38, p.S11-S16

Cobleigh, Melody A

2011

Volltextzugriff (PDF)

Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells

PloS one, 2020-06, Vol.15 (6), p.e0234146

2020

Volltextzugriff (PDF)

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Journal of clinical oncology, 2005-02, Vol.23 (4), p.792-799

2005

Volltextzugriff (PDF)

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

Advances in radiation oncology, 2019-07, Vol.4 (3), p.453-457

2019

Volltextzugriff (PDF)

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.719-726

2002

Volltextzugriff (PDF)

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin

Breast cancer research and treatment, 2016-02, Vol.156 (1), p.33-43

2016

Volltextzugriff (PDF)

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Clinical cancer research, 2011-01, Vol.17 (2), p.372-381

2011

Volltextzugriff (PDF)

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes

Clinical cancer research, 2005-12, Vol.11 (24), p.8623-8631

2005

Volltextzugriff (PDF)

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

Breast cancer research and treatment, 2013-11, Vol.142 (2), p.415-421

2013

Volltextzugriff (PDF)

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

Journal for immunotherapy of cancer, 2024-08, Vol.12 (8), p.e009160

2024

Volltextzugriff (PDF)

Reply to M. R. Van Bockstal et al

Journal of clinical oncology, 2021-10, Vol.39 (30), p.3410-3411

2021

Volltextzugriff (PDF)

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers

Breast cancer research and treatment, 2024-04, Vol.204 (2), p.407-414

2024

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Journal of clinical oncology, 2002-08, Vol.20 (15), p.3317-3327

2002

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2023-03, Vol.41 (9), p.1638-1645

2023

Volltextzugriff (PDF)

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Journal of clinical oncology, 2023-03, Vol.41 (8), p.1501-1510

2023

Volltextzugriff (PDF)

Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway

Breast cancer research and treatment, 2019-09, Vol.177 (2), p.325-333

2019

Volltextzugriff (PDF)

Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2367-2374

2021

Volltextzugriff (PDF)

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

Clinical cancer research, 2004-03, Vol.10 (6), p.1971-1975

2004

Volltextzugriff (PDF)

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

Oncology, 2001-01, Vol.61 (Suppl 2), p.37-42

2001

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.719-726

Vogel, C. L.

2002

Volltextzugriff (PDF)

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Seminars in oncology, 2003-10, Vol.30 (5), p.117-124

2003

Volltextzugriff (PDF)

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Journal of clinical oncology, 2005-01, Vol.23 (3), p.619-629

2005

Volltextzugriff (PDF)

Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.315-319

2017

Volltextzugriff (PDF)

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Breast cancer research and treatment, 2009-05, Vol.115 (1), p.115-121

2009

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(116)

Publikationsform

Artikel
(132)
Dissertationen
(1)

Sprache

Englisch
(133)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Other Options in the Treatment of Advanced Breast Cancer

Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment

Reply to M. R. Van Bockstal et al

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway

Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer

Suchergebnisse filtern